Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: clinical features, risk factors, and posaconazole profiles.
Sign Up to like & getrecommendations! Published in 2023 at "Medical mycology"
DOI: 10.1093/mmy/myad046
Abstract: Posaconazole (PSC) delayed-release tablet prophylaxis is the standard of care for preventing invasive fungal infection (IFI) in patients with acute myeloid leukemia undergoing myelosuppressive chemotherapy. The clinical features, risk factors, and PSC profiles of breakthrough… read more here.
Keywords: tablet prophylaxis; risk factors; myeloid malignancy; patients myeloid ... See more keywords
Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2019003105
Abstract: Aging is associated with significant changes in the hematopoietic system, including increased inflammation, impaired hematopoietic stem cell (HSC) function, and increased incidence of myeloid malignancy. Inflammation of aging ("inflammaging") has been proposed as a driver… read more here.
Keywords: mir 146a; hsc function; inflammation; malignancy ... See more keywords
Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020002854
Abstract: Invasive fungal disease (IFD) can be a severe treatment complication in patients with myeloid malignancies, but current risk models do not incorporate disease-specific factors, such as somatic gene mutations. Germline GATA2 deficiency is associated with… read more here.
Keywords: gata2 mutations; risk; disease; somatic gata2 ... See more keywords